CD274 and breast cancer: Collectively, these findings suggest that in situ induction and activation of cDC1s in the mammary tumors generates potent systemic antitumor immunity, delays the formation of established distant brain metastases, overcomes resistance to anti-PD-L1 therapy, renders them responsive to anti-PD-L1 therapy and improves survival.